Tashkent, Uzbekistan (UzDaily.com) -- Today, on 2 November, diplomats of the Consulate General of Uzbekistan met with Georgi Goh, vice president of the Jafron Biomedical pharmaceutical company, to identify promising areas of cooperation, Dunyo news agency reported.

The Chinese side was familiarized in detail with the work carried out in Uzbekistan in the fields of medical services, pharmaceuticals, as well as the conditions created for foreign companies.

In turn, the Vice President of one of the leading pharmaceutical companies not only in China, but throughout the world, Georgi Guo, thanked the diplomatic mission for the initiative and emphasized the high interest in establishing business with Uzbekistan. He emphasized that after the talks, Jafron Biomedical plans to study in more detail the possibilities of doing business in our country. “In a state with a population of more than 35 million people, and taking into account the reforms carried out in recent years aimed at improving life, including protecting the health of the population of Uzbekistan, we see good opportunities for mutually beneficial cooperation,” Georgi Goh said.

The Uzbek side proposed to consider the possibility of training Uzbek specialists on the use of high-tech equipment manufactured by Jafron Biomedical.

As a result of the negotiations, agreements were reached on holding working meetings at the level of specialists of the parties in order to develop more specific areas of interaction.

Founded in 1989, Jafron Biomedical is a global provider of technology, products and therapeutic services to the hemoadsorption industry with a market value of US$7 billion. The company is engaged in research, development, production and sales of blood purification products. Jafron Biomedical has 183 offices in China and five global service centers, including Vietnam, Europe, South America. With over 20 years of clinical experience, Jafron Biomedical’s HA series disposable hemoperfusion cartridge has been adopted by more than 8,000 key hospitals in 80 countries and regions. Its annual clinical use reaches 5 million cases.